First Revenues from Sales in Germany
PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com
FOR PUBLIC RELEASE
NZX Limited
Wellington
7
th
, June 2023
First Revenues from Sales in Germany
Rua Bioscience is excited to announce the first revenues from sales of products in Germany after the first full
month of sales. The response to the Rua products has exceeded our expectations and they been very well
received by pharmacists and patients
in the German market. In the first month of sale Rua has sold 13,000 grams
or 28 pounds of dried flower product.
The first revenues in Germany are a significant milestone for the company. As an early‐stage medicinal cannabis
company, achieving revenue is important to ensure the long‐term
sustainability of the company and returning
value to our shareholders.
The planning for this market launch by the combined marketing efforts of Nimbus Health and Rua Bioscience
teams has been in the pipeline for many months and we are pleased to see the results of our efforts. With an
established path
to market and revenue, Rua and Nimbus Health plan to expand the product offering in the
German market. In time, Rua will distribute the genetics from our Ruatorea facility through this same channel.
Paul Naske, CEO of Rua Bioscience expressed his thanks to all the staff and stakeholders of Rua
Bioscience who
have worked hard over the recent months and years to establish this pathway to market. The team have been
focused and methodical in their approach and dedication to the German market over many years.
This is a significant milestone of the strategy that Rua put in place in 2019
to create sustainable revenue and a
positive return to shareholders.
For more information about Rua Bioscience please visit www.ruabioscience.com.
ENDS
The person who authorised this announcement:
Paul Naske,
Chief Executive Officer
For shareholder enquiries please visit www.ruabio.com or contact:
info@ruabio.com
0800 RUABIO
MARKET ANNOUNCEMENT
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- ARB — ArborGen Holdings Limited: ArborGen expands internal eucalyptus production in Brazil2023-08-09
“ArborGen expands internal eucalyptus production in Brazil 9 August 2023 ArborGen Holdings Limited (NZX: ARB) advises it has acquired a eucalyptus seedlings nursery operation in Brazil located in the town of Erval Grande in Rio Grande do Sul State, referred to…”
- BLT — BLIS Technologies Limited: Revenue growth and a profitable second half year2023-05-24
“Blis Technologies Limited: Ground Floor, 442 Moray Place, Dunedin Central 9016, PO Box 2208, Dunedin 9044, New Zealand T:+64 3 474 0988 E: info@blis.co.nz W: www.blis.co.nz 25 May 2023 Revenue growth and a profitable second half year Blis Technologies Limited (N…”
- AFT — AFT Pharmaceuticals Limited: AFT Crystawash reg’n in China and new licencing agreements2023-03-26
“AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand Incorporated in New Zealand ARBN: ARBN 609 017 969 the progress we are making in realising the potential of our Maxigesic intellectual property. Additionally, w…”